Table 1a.

Summary of results from the patients included in the analyses from the phase III trial of sorafenib vs. placebo (TARGET).

	Sorafenib arm (n = 382)	Placebo arm (n = 388)
Mean ± SD number of target lesions used	2.1 ± 0.9	2.1 ± 0.9
Mean ± SD baseline tumor size (mm)	78.0 ± 55.1	79.6 ± 52.1
RR by RECIST at 6 weeks	10.5 %	1.0%
Mean ± SD % change in tumor size at 6 weeks vs. baseline	−5.9% ± 28.6%	15.3% ± 32.6%
Mean log ratio ± SD of tumor size at 6 weeks vs. baseline	−0.10 ± 0.29	0.11 ± 0.25